A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses

J Neurosci. 1999 Nov 15;19(22):9728-38. doi: 10.1523/JNEUROSCI.19-22-09728.1999.

Abstract

The involvement of adenosine on the development of time-dependent reversal of long-term potentiation (LTP) by low-frequency stimulation (LFS) was investigated at Schaffer collateral-CA1 synapses of rat hippocampal slices. A train of LFS (2 Hz, 10 min, 1200 pulses) had no long-term effects on synaptic transmission but produced lasting depression of previously potentiated responses. This reversal of LTP (depotentiation) was observed when the stimulus was delivered </=3 min after induction of LTP. However, application at 10 min after induction had no detectable effect on potentiation. This time-dependent reversal of LTP by LFS appeared to be mediated by extracellular adenosine, because it was mimicked by bath-applied adenosine and was specifically inhibited by the selective A(1) adenosine receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (100 nM). The effect of adenosine could be mimicked by 5-HT(1A) receptor agonist buspirone, but the LFS-induced depotentiation could not be antagonized by 5-HT(1A) receptor antagonist NAN-190. The source of extracellular adenosine in response to LFS appeared to be attributable to the efflux of cAMP. In addition, this LFS-induced depotentiation was blocked by bath application of adenylyl cyclase activator forskolin or injection of a cAMP analog Sp-adenosine cAMP (10 mM) into postsynaptic neurons. Moreover, the selective protein phosphatase 1 and 2A inhibitors okadaic acid and calyculin A prevented the LFS-induced depotentiation. These results thus suggest that increasing extracellular adenosine appears to underlie the LFS-induced depotentiation via acting on the A(1) receptor subtype to interrupt the cAMP-dependent biochemical processes leading to the LTP expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / physiology*
  • Animals
  • Buspirone / pharmacology
  • Colforsin / pharmacology
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Electric Stimulation
  • Enzyme Inhibitors / pharmacology
  • Excitatory Postsynaptic Potentials
  • Hippocampus / physiology*
  • In Vitro Techniques
  • Least-Squares Analysis
  • Long-Term Potentiation / drug effects
  • Long-Term Potentiation / physiology*
  • Male
  • Neurons / drug effects
  • Neurons / physiology*
  • Piperazines / pharmacology
  • Purinergic P1 Receptor Antagonists
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / physiology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Serotonin / physiology
  • Receptors, Serotonin, 5-HT1
  • Serotonin Antagonists / pharmacology
  • Serotonin Receptor Agonists / pharmacology
  • Synapses / drug effects
  • Synapses / physiology*
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Theobromine / analogs & derivatives
  • Theobromine / pharmacology
  • Thionucleotides / pharmacology
  • Time Factors
  • Xanthines / pharmacology

Substances

  • Enzyme Inhibitors
  • Piperazines
  • Purinergic P1 Receptor Antagonists
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT1
  • Serotonin Antagonists
  • Serotonin Receptor Agonists
  • Thionucleotides
  • Xanthines
  • 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine
  • Colforsin
  • adenosine-3',5'-cyclic phosphorothioate
  • 3,7-dimethyl-1-propargylxanthine
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Cyclic AMP
  • Adenosine
  • Theobromine
  • Buspirone